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Background:Hematopoietic stem cell transplant in mucopolysaccharidosis I (MPSI) patients often results in graft failure.
Results: In mice with MPSI we link reduced hematopoietic engraftment post-transplant to accumulated overly-sulfated extra-
cellular heparan sulfate.
Conclusion: Excess extracellular heparan sulfate alters cytokine gradient formation, restricting stem cell migration.
Significance: This provides a mechanistic insight into the observed engraftment difficulties seen in patients.
Mucopolysaccharidosis I Hurler (MPSI-H) is a pediatric lyso-
somal storage disease caused by genetic deficiencies in IDUA,
coding for -L-iduronidase. Idua/mice share similar clinical
pathology with patients, including the accumulation of the
undegraded glycosaminoglycans (GAGs) heparan sulfate (HS),
and dermatan sulfate (DS), progressive neurodegeneration, and
dysostosis multiplex. Hematopoietic stem cell transplantation
(HSCT) is the most effective treatment for Hurler patients, but
reduced intensity conditioning is a risk factor in transplanta-
tion, suggesting an underlying defect in hematopoietic cell
engraftment. HS is a co-receptor in the CXCL12/CXCR4 axis of
hematopoietic stem and progenitor cell (HSPC) migration to
the bonemarrow (BM), but the effect ofHS alterations onHSPC
migration, or the functional role ofHS inMPSI-H are unknown.
We demonstrate defective WT HSPC engraftment and migra-
tion in Idua/ recipient BM, particularly under reduced inten-
sity conditioning. Both intra- but especially extracellular
Idua/BMHSwas significantly increased and abnormally sul-
fated. Soluble heparinase-sensitiveGAGs from Idua/BMand
specifically 2-O-sulfated HS, elevated in Idua/ BM, both
inhibited CXCL12-mediated WT HSPC transwell migration,
while DS had no effect. Thus we have shown that excess overly
sulfated extracellular HS binds, and sequesters CXCL12, limit-
ing hematopoietic migration and providing a potential mecha-
nism for the limited scope of HSCT in Hurler disease.
Mucopolysaccharidosis type I (MPSI)2 is an inherited meta-
bolic disease caused by a deficiency of -l-iduronidase (IDUA),
which leads to accumulation of heparan sulfate (HS) and der-
matan sulfate (DS). Hurler disease (MPSI-H) is the most severe
form, presenting in infancy with symptoms of skeletal dyspla-
sia, abnormal facies, organomegaly, cardiac and respiratory
defects, severe neurological degeneration, and death (1). Atten-
uated forms of the disease have much less significant neurolog-
ical involvement and improved lifespan.
There are two current clinical treatment modalities for
MPSI. Pharmacological enzyme replacement therapy (ERT),
which relies on mannose-6-phosphate mediated uptake and
cross-correction of affected cells, has limited effect on bone and
neurological manifestations, as the enzyme fails to cross the
blood brain barrier. Thus, ERT is only licensed for use in atten-
uated forms of MPSI (2, 3). Hematopoietic stem cell transplan-
tation (HSCT) is an attractive alternative therapy, relying on the
ability of donor derived monocytes to traffic and engraft in the
brain as microglial cells (4), releasing enzyme here for cross
correction.However, while successful transplants have resulted
in significantly improved patient outcomes in MPSI-H, with
extended life and improved neurological function, successful
stable donor chimerism is difficult to achieve, with 44% of
patients requiring a second or third transplant (5, 6). Risk fac-
tors identified in bone marrow (BM) and umbilical cord blood
transplantation include reduced intensity conditioning regi-
mens and age of treatment, with earlier treatment resulting in
improved clinical outcomes. Recently, the introduction of fully
myeloablative busulfan/cyclophosphamide conditioning (5–7),
has significantly improved transplant success rates to over 90%
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in some centers, but this requirement suggests an underlying
engraftment defect inMPSI patients in one or all of hematopoi-
etic stem cell maintenance, homing, or engraftment.
HS, which is stored to pathological excess inMPSI-H (8–10),
is involved in all aspects of these processes, including signaling
involving CXCL12 (11, 12), as well as the presentation of
chemokines to ligands in haptotactic gradients (13, 14). HS is
synthesized covalently linked to a core protein to form an HS
proteoglycan (HSPG), which are found at the cell-matrix inter-
face. HS is a long chain non-branching sulfated glycosamin-
oglycan (GAG), consisting of repeating disaccharide subunits
ofN-acetyl glucosamine (GlcNAc) and glucuronic acid (GlcA).
The chain is modified in the Golgi apparatus during synthesis
by the epimerization of a subset of GlcA residues to iduronic
acid (IdoA) and the transfer of sulfates to the N-, 2-O-, 3-O-,
and 6-O-positions, selectively altering regions of the chain to
patches of modification, known as sulfated (S-) domains, sepa-
rated by regions with little modification. Ultimately it is these
modifications which determine the ability of the chain to bind
different protein factors (15). Heparin is structurally similar to
HS but lacks a domain structure, being very heavily modified
along the entire chain.
CXCL12 via its cognate receptor CXCR4, is the primary
mediator of hematopoietic stem and progenitor cell (HSPC)
homing to the BM following transplantation (16). It is consti-
tutively expressed by the BM, and expression is up-regulated
following DNA damage and hypoxia, which both result from
myeloablative transplant conditioning (17, 18). CXCL12 is pre-
sented to incoming cells via HS on the apical surface of endo-
thelial cells, and cannot function in vivowithout its HS binding
site (19), which is structurally unique among cytokines, and
exhibits a binding preference for regions containing 2-O-sulfa-
tion (20).
Here, we demonstrate that engraftment difficulties seen in
the clinic are recapitulated in a mouse model of MPSI-H, and
that the decrease in engraftment can be linked to a decrease in
homing of transplanted cells to the BM. The BM of these mice
contains significant amounts of stored HS, but rather than the
HS being sequestered within the lysosomes, it is instead over-
whelmingly located in the extracellular matrix of the BM
stroma, making it available for protein interactions. The accu-
mulated HS is rich in the 2-O-sulfation modification preferred
by CXCL12, while levels of CXCL12 are increased in the BM
niche of affected mice. However, we demonstrate that rather
than improving migration of HSPCs to the BM, the excess,
highly sulfated HS is inhibiting migration toward CXCL12,
resulting in homing and engraftment defects.
EXPERIMENTAL PROCEDURES
Mice—Donor and recipient mice differentially expressed
CD45 epitopes using crosses of B6.SJL-PtprcaPepcb/BoyJ
(CD45.1) (Jackson Laboratories), C57BL6 (CD45.2) and
heterozygote CD45.1xCD45.2 F1 mice, generated on WT or
B6.129-Iduatm1Clk/J (Idua/) backgrounds (21). Mice were
maintained according to UK Home Office regulations with
food and water ad libitum.
BM Transplantation—6–9-week-old recipient mice were
maintained on acidified water and irradiated feed for 7 days
prior to transplant.Mice were either lethally irradiated in two 5
Gy doses 4 h apart (full intensity), or myeloablated using 125
(full intensity) or 25 mg/kg (reduced intensity) Busulfan (Busil-
vex, Pierre Fabre), via intraperitoneal injection as previously
described (22–24). Fresh whole bone marrow or lineage-de-
pleted cells were delivered via tail vein 1 h post-irradiation or
24 h post-Busulfan. Mice were sacrificed at 18 h (whole BM
migration), 36 h (lineage depleted migration) 6 weeks (short
term engraftment), or 20 weeks (long term engraftment) and
BM, peripheral blood, spleen recovered and analyzed by flow
cytometry tomeasure donor chimerism as previously described
(22).
Leukocyte Preparation—BM or blood was collected, washed
and erythrocytes lysed using ammonium chloride lysis.
Extracted leukocytes were re-suspended in PBS/2% FCS for lin-
eage negative separation (Stem Cell Technologies) or Sca1
separation (Miltenyi) using double LS column selection,
according to manufacturer’s recommendations. Enriched cell
populations were resuspended in X-Vivo10 for migration and
whole BM stored in at  80 °C in 10% DMSO/40% FCS. For
quantification of total BM, cells from only one femur and one
tibia per mouse were extracted and counted. Colony-forming
assayswere performed in triplicate as described previously with
2  104 cells/ml for BM and 1  105 cells/ml for peripheral
blood and counted 12 days later (22–24).
CXCL12 Quantification—Quantification of CXCL12 was
performed using a quantitative immunosorbant assay kit (R&D
Systems) on the soluble fraction of BM extracted from a single
femur and tibia in a total volume of 200 l of PBS, and centri-
fuged at 300 g to remove cells.
Bone Marrow Stromal Cell Culture—BM cells were isolated
and lysed as described, but with additionalmechanical abrasion
of the interior of the bones using a 29 Gneedle, to extractMSCs
residing at the endosteum (25). Cells were cultured in -MEM
(Lonza) with 12.5% horse serum, 12.5% FCS, 0.1 M hydrocor-
tisone, 2 mM L-glutamine, and 50 units of penicillin/50 g of
streptomycin. Passage 5–15 cells were characterized by flow
cytometry with the following expression profile: CD45,
CD11b, Sca1, CD44hi, CD105.
In Vitro Migration Assays—Solutions of HS, DS, or selec-
tively desulfated heparins (Iduron), or 0.1% gelatin (Sigma) was
used to coat the insert of a transwell plate (Costar 6.5 mmwell,
5 m pore inserts). Prior to migration, excess coating solution
was aspirated, and inserts were washed once in PBS. Formigra-
tion toward CXCL12, migration medium (X-Vivo 10)  200
ng/ml CXCL12 (R&D) was added to the lower well (n 8). For
all assays, cells were counted in triplicate and resuspended at
1 107 cells/ml for whole, unsorted BM, or 1 105 for HSPC
enriched populations, in migration medium (X-VIVO 10,
Lonza/5% FCS. Cells in 100 l migration medium were added
to the insert andmigrated for 4 h at 37 °C. Formigration toward
the soluble fraction of BM, the pelvis, femurs and tibias of each
mousewere flushed into 1ml of PBS, pooled, and centrifuged at
300 g to remove cells. 500l of undiluted soluble fractionwas
added to the lower well of the migration plate.
For preparation of purified glycosaminoglycans, soluble BM
fractions were collected as above, and processed as described
previously (10). GAGswere freeze dried and resuspended in the
Accumulated HS Inhibits HSPC Engraftment inMPSI
DECEMBER 26, 2014•VOLUME 289•NUMBER 52 JOURNAL OF BIOLOGICAL CHEMISTRY 36195
relevant starting volume of PBS. A portion of Idua/ GAGs
were digested with heparinases as described previously (10).
2  105 lineage depleted BM cells/well were migrated in the
presence of 2% FCS/6.25% GAGs in X-VIVO 10 toward
CXCL12 (200 ng/ml) for 8 h at 37 °C across gelatin-coated
5-m pore transwell inserts. Migrated and un-migrated cells
were counted by flow cytometry (BD FACSCanto II) using
CytoCount Control Beads (Brookhaven Instruments Ltd).
Flow Cytometry—All flow cytometry was carried out on a BD
FacsCANTO II flow cytometer, using FacsDiva (BD), FlowJo
(TreeStar) or Weasel (WEHI Institute) software for analysis.
ToPro3 (Invitrogen) or 7AAD (BD Biosciences) were used as
viability stains. For the identification of hematopoietic stem
and progenitor populations, the following antibodies were
used: RatMouseC-Kit FITC; LineageMixture (CD3e, CD11b,
CD45R, TER-119, Ly6G, Ly6C)APC; RatMouse Sca-1 PE; Rat
Mouse CD45 APC-Cy7 (all BD Biosciences). For the identifi-
cation ofmature hematopoietic lineages, the following antibod-
ies were used: Rat Mouse CD11b PE-Cy7; Rat Mouse CD19;
Rat Mouse CD3 PerCPCy5.5 (all BD Biosciences). For mea-
surement of donor chimerism: Mouse Mouse CD45.1 PE;
MouseMouseCD45.2 (BDBiosciences). For the characteriza-
tion of MSCs: Rat Mouse C-Kit FITC; Rat Mouse CD11b
PE-Cy7; Rat Mouse Sca-1 PE; Rat Mouse CD45 APC-Cy7;
Rat Mouse CD44 PerCP Cy5.5; Rat Mouse Sca-1 PE-Cy7
(BD Biosciences), and Rat Mouse CD105 FITC (R&D Sys-
tems). For the analysis of HS, the following phage display scFv
antibodies were used: HS4C3, RB4EA12 and MPB49 as
described previously (26, 27).
Immunofluorescence—WT and MPSI MSCs were cultured
on Permanox chamber slides (Lab-Tek) and fixedwith 4%para-
formaldehyde, staining as described previously (27). Where
required, slides were treated with 2mIU heparinase I, II, and III
in PBS for 1 h at room temperature prior to permeabilization.
Antibodies used were LAMP2 (University of Iowa), 10E4 and,
3G10 (both Seikagaku), rat-Alexa546, mouse IgM-Alexa488,
and mouse IgG-Alexa488 (all Invitrogen). Images were col-
lected using a Nikon C1 confocal on an upright 90i microscope
with a 60 oil immersion objective, with z-stacked images col-
lected at 0.5-m intervals. Images were processed in ImageJ
(NIH/MacBiophotonics) and presented as z-projections at
maximum intensity.
GAG/CXCL12 ELISA—BD Heparin Binding Plates (BD Bio-
sciences) were used in all assays. HS, DS, and heparin (Iduron)
were dissolved in PBS at concentrations of 0.05–12.8 M based
on approximate “average” disaccharide MWs. Plates were
coated with GAG overnight at room temperature then washed
withWash Buffer (100 mMNaCl, 50 mMNaAc, 0.2% Tween20,
pH6.0), blockedwithWashBuffer1%BSA (Sigma) for 90min
at 37 °C. Following incubation with 200 ng/ml CXCL12 in PBS
for 90 min at 37 °C, wells were blocked with Wash Buffer/5%
goat serum (Vector Labs) before adding 1:1000 polyclonal rab-
bit human CXCL12 antibody (AbCam) for 1 h at room tem-
perature.Wells were stainedwith biotinylated goatrabbit IgG
(Vector Labs,1:2000), amplified with Vectastain Elite ABC
reagent (Vector Labs) and developed with OPD substrate
(Sigma) as per manufacturer’s instructions. Absorbance at 490
nm was measured using a Synergy HT Microplate Reader
(BioTek).
2-Aminoacridone (AMAC) Labeling for High Performance
Liquid Chromatography Disaccharide Analysis—Leukocytes
were extracted as described above. Supernatant from all wash
and lysis steps was reserved for the extracellular niche fraction.
The cell pellet was resuspended to form the cell fraction. Gly-
cosaminoglycan chains were then purified, AMAC labeled and
analyzed by RP-HPLC essentially as described previously (10).
Because the efficiency of AMAC labeling varies according to
specific disaccharides, the raw peaks were multiplied by the
following correction factors determined by comparison to UV
traces for individual disaccharides: UA2S-GlcNS6S, 1.25;
UA-GlcNS(6S) 1.13; UA(2S)-GlcNS, 1.0; UA-GlcNS, 1.04;
UA-GlcNAc(6S), 1.13; UA(2S)-GlcNAc, 0.97; UA-GlcNAc,
1.08. Quantification of the amount of HS contained within cell
and matrix fractions was made by comparison of fluorescence
with known quantities of HS.
Statistical Analysis—Comparisons of means was performed
using either a two-tailed Student’s t test, or one-way or 2-way
ANOVAusing JMP software (SAS Institute Inc.) appropriate to
the number of means and variables compared. Post-hoc analy-
sis used Tukey’s multiple comparisons. p values of less than or
equal to 0.05were considered significant. Error bars refer to the
standard error of mean.
RESULTS
Idua/ Mice Demonstrate a Defect in HSPC Engraftment
and Bone Marrow Migration—To establish if an engraftment
defect was present in MPSI and to mimic the treatment
approach used in MPSI-H patients, we used HSCT in the
Idua/ mouse model, which accumulates HS and DS and
shares similar neuropathological features with MPSI patients
(21, 28). Following full myeloablation of Idua/ or WT mice
and transplantation with WT BM (23), full donor chimerism
was achieved in all recipients at 6 weeks (Fig. 1A), although a
small but statistically significant decrease in peripheral blood
and spleen donor chimerism in Idua/ recipients was
observed. We introduced limiting conditions for engraftment
with reduced-intensity conditioning, resulting in a highly sig-
nificant engraftment defect in Idua/ recipients at both high,
or low cell doses (Fig. 1B).
Previous analysis of mesenchymal stromal cells (MSCs)
derived from bone marrow of MPSI-H patients, suggested that
theywere not able tomaintain the colony-forming properties of
HSCs as well as normal MSCs (29). This implied that the BM
niche may be detrimental to hematopoiesis in MPSI. However,
our analysis of total leukocytes in the BM suggested normal
hemostasis in MPSI mice (Fig. 2A), supported by analysis of
phenotypic markers of mature and naive hematopoietic popu-
lations (Fig. 2, A and B) and colony forming ability in the BM
(Fig. 2C), both of which indicated no abnormality in the main-
tenance of mature or naive hematopoietic lineages in Idua/
BM. Interestingly, we did observe reduced colony forming units
(CFU) in the peripheral blood of Idua/ mice (Fig. 2D), sug-
gesting retention of HSPCs in the Idua/ BM compartment.
Short-termanalysis of the ability ofWTdonorBMtomigrate
to the myeloablated bone marrow of recipients, revealed a sig-
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nificant decrease in the number ofWTdonor cells reaching the
BM compartment in Idua/ recipients (Fig. 3A), that became
more pronounced when using a donor BM lineage negative
fraction enriched forHSPC (Fig. 3B). ReducedHSPCmigration
might suggest a decrease in the production of the chemokine
CXCL12, known to be responsible for HSPC migration and
retention in the Idua/ BM. However, analysis of CXCL12
concentration in the BM niche revealed significantly increased
concentrations in Idua/ BM both before and after myeloab-
lation (Fig. 3, C and D). Therefore the observed homing and
engraftment defects are not due to decreased CXCL12. On the
contrary, elevated levels of CXCL12 in the Idua/ BM (Fig. 3,
C and D) may be responsible for the decreased levels of circu-
latingHSPC observed in (Fig. 2D), supporting the hypothesis of
increased retention of HSPCs in the BM niche.
Idua/ Bone Marrow Contains Excess Intra- and Extracel-
lular HS in Non-lysosomal Locations That Is Rich in Sulfate
Modifications, Particularly 2-O-Sulfation—CXCL12 relies on
GAGs to form haptotactic gradients, which are thought to
guide CXCL12 mediated migration (12). In addition, CXCL12
contains a uniqueHS binding site (11), permitting dimerization
and CXCR4 receptor binding. CXCL12 binding is furthermore
dependent on the level and pattern of sulfation ofHS (11, 20, 30,
31). Thus we reasoned that alterations in the level and sulfation
patterning of HS could alter the ability of HSPCs to migrate to
CXCL12 gradients. Previous studies have been conflicting
regarding quantities of HS stored and the level of sulfation in
MPSI (32–34), and althoughwe have identified similar patterns
of increased and abnormally sulfated HS in tissue and serum in
both Idua/ mice and MPSI patients (10), the BM has not
been examined, nor the relative levels of intra- and extracellular
HS quantified.
Biochemical analysis of the composition ofHS in cellular and
extracellular BM fractions, using reverse-phase HPLC and
AMAC labeling (35), indicated that there is a significant
increase in all sulfated disaccharides in both BM fractions in
Idua/mice, with the greatest increase being in overall levels of
2-O-sulfate and N-sulfate modifications, and in particular, the
HexA(2S)-GlcNS and HexA(2S)-GlcNS(6S) disaccharides (Fig.
4,A and 4B). Notably the proportion of disaccharides which are
N-sulfated within Idua/ BM exceeds those which are
N-acetylated. The most marked increase in HS accumulation
was observed in the soluble extracellular BM fraction, not the
cell fraction; a 33-fold increase in extracellular HS (average of
0.28 g HS per WT BM compared with 9.4 g of HS in
Idua/) was visible compared with a 2.4-fold increase (aver-
age of 0.31 g of HS inWT BM versus0.73 g in Idua/) in
the cell fraction (Fig. 4C). Interestingly, WT BM has similar
amounts of HS in the cell and extracellular fractions. However
most of the excess stored HS in Idua/ BM is in the extracel-
FIGURE 1. There is a significant defect in engraftment in Idua/ mice
under limitingconditions.A, donorCD45 cell chimerism inhematopoietic
organs of Idua/ and WT mice 6 weeks after full intensity busulfan myelo-
ablation and transplant of 2 106 WT bonemarrow cells (WT n 4, Idua/
n 6). B, donor CD45 cell chimerism in peripheral blood of Idua/ and WT
mice 20weeks after reduced intensity busulfanmyeloablation and transplant
of 1107 (highdose) or 2106 (lowdose)WTbonemarrowcells (n5). Two
Idua/ recipients died prior to 20weeks. Error bars represent standard error
of mean (S.E.).
FIGURE 2. BM Hematopoiesis is normal in Idua/ mice, but circulating
HSPCsare significantlydecreased.A, total leukocytes isolated froma single
femur and tibia of WT or Idua/ mice (n  3–7). Relative proportion of
mature hematopoietic lineages in bonemarrowmeasuredby flow cytometry
(n 9–10). Data from four independent experiments. B, flow cytometric gat-
ing and expression profile of C-Kit, Lin, Sca1(KLS) stem cell markers in
WT and Idua/ mice. Proportion of KLS expressing BM cells (n  8). Data
from four independent experiments. C, colony-forming ability of BM or D,
peripheral blood from age-matchedWT and Idua/mice and total colonies
per plate (n 7). Error bars represent S.E.
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lular BM niche, (13-fold more than is stored in the cell frac-
tion); the same location in which we found elevated levels of
CXCL12 (Fig. 3,C andD). Analysis of CD45, CD105, CD44
primary BM derived MSCs with phage-display scFv antibodies
directed against specific three-dimensional sulfated HS
epitopes, supports the disaccharide analysis, with increased
binding of HS4C3 and RB4EA12 (Fig. 4D), both of which have
been shown to recognize highly sulfated epitopes in HS,
enriched for 6-O- and N-sulfation (36–38).
The 10E4 epitope lies in N-sulfated regions of the HS chain,
but is destroyed through the combined and complete action of
bacterial heparinases. Immunofluorescent staining of HS in
MSCs confirmed a significant increase in cellular and matrix
HS (Fig. 5A). Furthermore there was a marked absence of HS
co-localized with LAMP2 in the lysosomal compartment, in
agreement with our previous findings (10). Controlled hepari-
nase treatment of Idua/MSCs prior to permeabilization and
staining, revealed non-lysosomal associated perinuclear 10E4
staining within the cell (Fig. 5B), co-localizing with the Golgi
marker giantin. This staining was not strongly visible in WT
cells (Fig. 5B). Therefore accumulated HS in BM MSCs is
observed at the cell surface, in the ECM and in both lysosomal
andnon-lysosomal compartments. The 3G10 epitope is created
by the action of heparinases, recognizing the unsaturated
uronic acid stub remaining attached to proteoglycan cores (40).
Thus it can provide information on the distribution of HS
chains and therefore the proteoglycan cores within a tissue and
potentially the number ofHS chains (as only one 3G10 antibody
can bind per chain). In WT cells, punctate 3G10 staining fol-
lowing heparinase digestion was seen across the surface of cells
(Fig. 5C). However staining of Idua/ cells revealed extensive
cell surface and ECM staining, with much of the epitopes
remaining in tight bundles spanning across cell junctions (Fig.
FIGURE 3.Homing to the Idua/ BM is impaired despite increased niche
CXCL12.A, flowcytometric quantificationofpercentageofCD45-positiveWT
donor BMcells orB, lineage-depleteddonorWTHSPCsmigrating to theBMof
WT or Idua/ recipients following lethal myeloablation and transplant with
2 107 donor cells (n 5–6). C and D, CXCL12 concentration in BM soluble
fraction of WT and Idua/mice, measured by quantitative ELISA (n 5–15)
in untreated mice (C) or 4 h after full myeloablation (D) (n 5–6). Error bars
represent S.E.
FIGURE 4. Elevated amounts of abnormally sulfated HS in the intra- and extracellular bonemarrow niche of Idua/mice. Disaccharide analysis of HS
in the cellular (A) and extracellular (B) fraction of whole BM from Idua/ and WT mice was quantified by AMAC-tagged compositional analysis following
complete digestion of the HSwith combined heparinases. Inset: percentage contribution fractions for each sulfation position. C, total amount of HS in cellular
and extracellular BM fractions. Amount of Idua/ BM is expressed as g HS per bone marrow calculated from AMAC fluorescent readings compared with
readings frommeasured amounts ofHS standards. Data are compiled fromaminimumof 5 separatemice of eachgenotype, separately digested, and analyzed
at least twice.D, flowcytometric analysis ofWTor Idua/bonemarrow-derivedMSCsusingHS-pattern specific antibodies.MPB49 is a non-HSbinding control
antibody. Data representative of eight independent experiments. Error bars represent S.E.
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5C). Again little co-localizationwith LAMP2was apparent. The
retention of the 3G10 epitope suggests that at least a proportion
of the stored HS chains in the ECM of Idua/ cells are
attached to proteoglycan cores rather than the HS chains being
free, thus aiding retention of HS within the extracellular
compartment.
Highly Sulfated HS from Idua/ Bone Marrow Inhibits
CXCL12-mediatedHSPCMigration—The increase inHS in the
bone marrow compartment suggested that excess HS may
inhibit CXCL12 function in migration, in contrast to previous
findings (12). Thereforewe used amigration assay to determine
if the HS produced by Idua/ animals was indeed inhibitory.
In agreement with our in vivo data we established that the sol-
uble extracellular fraction of Idua/ BM significantly reduced
CXCL12-mediated transwell migration of lineage negativeWT
HSPCs, comparedwithWT supernatant (Fig. 6A). To eliminate
the possibility of protein interactions, including CXCL12 satu-
ration, being responsible for the inhibition of migration, GAGs
chains were purified from Idua/ or WT BM, including a
protease and boiling step to degrade/denature co-purified pro-
teins. Purified Idua/GAGs resulted in a similar reduction in
CXCL12 mediated migration of WT HSPC to CXCL12 (Fig.
6B). Critically this effect was eliminated by pre-treating the
purified GAGs with HS-degrading heparinases prior to tran-
swell migration, ruling out involvement of excess DS or chon-
droitin sulfate, and confirming a role for HS in decreasedHSPC
migration (Fig. 6B).
Highly Sulfated HS and Heparin Bind CXCL12 in a Dose-de-
pendentManner—Adose-dependent decrease inCXCL12-me-
diated HSPC migration was also obtained when increasing
amounts of HS were immobilized on the transwell migration
membrane (Fig. 6C). Thus, suggesting that both soluble and
immobilized HS can block migration. To demonstrate that HS
was binding CXCL12 in a sulfation and dose dependent man-
ner, GAG was immobilized on the membrane, incubated with
CXCL12, washed, and then a CXCL12 antibody was used to
probe for CXCL12-GAG binding. Only high concentrations of
HS (10 M) were effectively able to capture CXCL12. Heparin,
which is a fully sulfated analog of HS, bound CXCL12 at lower
concentrations than HS (Fig. 6D), whereas DS was unable to
bind. This is in keeping with previous work (20) showing that
CXCL12 preferentially binds to the sulfated regions of HS
(which in HS are normally interspersed by regions of low sulfa-
tion modification).
2-O-Desulfation of Heparin Rescues CXCL12-mediated
Hematopoietic Migration—Finally, we coated transwell mem-
branes with selectively desulfated heparin, to highlight the
importance of different sulfate residues, and observed their
effect on CXCL12-mediated migration of WTHSPC. HS, 6-O-
desulfated and N-desulfated heparin reduced overall HSPC
migration, mimicking the effect seen with Idua/ BM GAG
fractions; both 2-O-desulfated heparin and DS had no inhibi-
tory effect (Fig. 6E). Thus these data strongly suggest that 2-O-
sulfation is essential for CXCL12 binding and excess 2-O-sul-
fated HS in Idua/ animals binds and functionally inhibits
CXCL12-mediated HSPC migration, a modification which we
found to be over-represented in Idua/ BM.
DISCUSSION
The ability of most lysosomal enzymes to cross-correct
neighboring cells via themannose-6-phosphate pathwaymakes
HSCT an attractive treatment option for lysosomal diseases.
Despite this, HSCT is still only used for a handful of lysosomal
diseases, including MPSI-H. Reduced intensity conditioning
could significantly improve the safety of HSCT in MPSI-H,
potentially broadening its scope to attenuated disease. In prin-
ciple, stable mixed chimerism is all that should be required for
cross-correction, however reduced intensity conditioning reg-
imens are rarely successful, and the reasons for this are not well
understood (5, 6). Previous studies have investigated the effect
of HS/DS storage on developmental signaling pathways, how-
ever conclusions regarding the nature of the accumulated HS,
and thus its effect on signaling pathways, have been contradic-
FIGURE 5. HS is accumulated in non-lysosomal intracellular compart-
ments including the Golgi. A, confocal images of MSCs fromWT or Idua/
mice stained for the lysosomal marker LAMP2 (red) and HS (10E4, green).
Nuclei were stained with DAPI. Scale bar 50 m. B, WT and Idua/MSCs
were treated with heparinizes prior to permeabilization and subsequently
stained with Giantin and 10E4. Scale bar 25 m. C, WT and Idua/MSCs
were treated with heparinizes prior to permeabilization and subsequently
stained with Lamp2 and 3G10. Scale bar 50 m.
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tory (32, 34) or inconclusive (41). To date there have been no
investigations into the possible effects of accumulated HS on
pathways important for disease treatment. Here, we sought to
determine whether the stored HSmay have a functional role in
HSPC migration and engraftment in MPSI-H, to enable a
greater understanding of why reduced intensity conditioning
HSCT is usually unsuccessful in the clinical setting.
Using the Idua/ mouse model of MPSI-H we demon-
strated that there is a defect in both HSPC migration and
engraftment in MPSI-H. However, interestingly the engraft-
ment defect is only significant under limiting transplant condi-
tions, while the migration defect is measurable even at saturat-
ing cell doses and full myeloablation. This suggests that the
migration defect is constitutive but only contributes to graft
failure under sub-optimal conditions for graft acceptance,
where cell numbers are limiting, or where reduced intensity
conditioning is used. The absence of an engraftment defect in
non-limiting conditions, together with evidence that hemato-
poiesis and hemostasis in the Idua/mouse are indistinguish-
able from WT, suggests a BM niche that is supportive of
engraftment.
In challenge to the current understanding of lysosomal stor-
age diseases, we demonstrated a 13-fold excess of HS in extra-
cellular locations in the Idua/ BM niche, at least some of
which is still bound to a protein core, presenting a system in
which it is possible that multiple signaling pathways may be
altered. Notably, the detection of non-reducing HS end struc-
tures in the plasma of patients withMPSI (42), suggests that HS
is being partly degraded in the lysosome and released. The large
excess of HS that we see in the ECM, existing most likely as a
mixture of proteoglycan “bound” 3G10 positive cores and free
10E4 positive chains may be contributing to reduced mobility
FIGURE 6. Extracellular and 2-O sulfated HS in MPSI inhibits migration in a dose dependent manner. A, transwell migration of WT Lin- cells toward
exogenousCXCL12 added to the soluble fractionofWTor Idua/BM (n8). Negative control ofWT soluble fractionwithout exogenousCXCL12 is equivalent
to 7.1% B, transwell migration ofWT Lin- cells toward exogenous CXCL12 added to the Pronase treated glycosaminoglycan fraction ofWT or Idua/ BM (n
20)withorwithoutheparinasepre-treatment.C, representative curveofWTBMmigrated towardCXCL12acrossHS-coated inserts at increasingconcentrations
(n 4).D, comparison of CXCL12 binding to increasing concentrations of immobilized GAGs (n 3). E, transwell migration of Lin- WT cells acrossmembranes
coatedwith 15MHS,DS and2-O, 6-O, andN-desulfatedheparin (n 4). Positive control of uncoatedmembrane is equivalent to 11.2%. Error bars represent
S.E.
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of HS in and out of cells. This results in accumulation in the
ECMand consequential sequestration of cytokines and chemo-
kines including CXCL12, thus altering critical signaling
pathways.
CXCL12-mediated homing of HSPCs to the BM following
transplantation relies on the formation of appropriate haptot-
actic gradients involvingHS (Fig. 7). The requirement for HS in
CXCL12-mediatedmigration is demonstrated in a study where
mice expressed a mutant form of CXCL12 unable to bind HS.
Increased circulating CXCL12 and reduced migration of
CD34 cells to sites of ischemic injury was observed due to an
absence of haptotactic CXCL12 gradients (43). Furthermore, it
has been shown that entry and egress of HSPCs to the bone
marrow may be controlled through manipulations of HS. For
instance, a number of studies (30, 31), have indicated that
increases in circulating GAG mimetics lead to egress of
CXCL12 from the BM niche into circulation, and a concomi-
tant mobilization of circulating HSPCs. We have previously
shown elevatedHS in the circulation of the Idua/mouse and
MPSI patients (44, 45), which might be expected to behave in
the same way as circulating GAG mimetics, increasing HSPC
egress from the BM. However, within the Idua/ mouse, the
significant increase in BMnicheHS is converselymitigating the
effect of circulatingHS, essentially trapping CXCL12 in the BM
niche, and consequently decreasing circulating HSPCs. The
CXCL12 gradients presented in Fig. 7might suggest thatmigra-
tion would be normal in the Idua/mouse (CXCL12 being at
the highest concentration where HS is most localized, in the
BM), and possibly even better than WT, given the higher con-
centration of CXCL12. However, our observations, together
with previous studies on the affinity of CXCL12 for 2-O-sul-
fated HS, suggest that high-affinity binding of CXCL12 by
heavily sulfated Idua/HS is preventing CXCL12 from form-
ing effective haptotactic gradients, resulting in sequestration of
CXCL12 in the BM (Fig. 7B).
Although full intensity busulfan conditioning, does not
increase the numbers of donor HSPC reaching the BM (46), it
does provide a more permissive environment for engraftment
of donor HSPC by eliminating a greater proportion of recipient
BM, thus creating niche space. The defect in HSPC migration
and excess of GAG in Idua/ BM strongly suggest that HSCT
in HS storage diseases such asMPSI-H should use full intensity
conditioning, and provide a mechanism by which this strategy
is successful in improvingMPSI patient engraftment outcomes
(5, 7). Our data also suggest that strategies such as ERT, which
reduce the amount of HS in and around cells prior to trans-
plant, may improve donor chimerism outcomes by reducing
HS-mediated homing inhibition in patients. MPSI-H patients
are known to raise significant inhibitory antibody responses to
ERT that are subsequently abolished by successful HSCT (39).
Thus, abbreviated pre-transplant ERT regimensmay be prefer-
able to avoid inactivation of delivered enzyme prior toHSCT to
maximize outcomes, and this warrants further investigation.
In conclusion, we show that highly 2-O-sulfated HS is pres-
ent in excess in extracellular locations in the BM in MPSI-H,
and in this context has an unexpected role in inhibiting HSPC
migration into, and out of, the BM by sequestering CXCL12.
Our data further define the functional role of HS in CXLC12-
mediated HSPC migration and suggest a viable treatment
approach for achieving successful outcomes with HSCT after
reduced intensity conditioning in MPSI-H.
Acknowledgments—We gratefully acknowledge the help and assis-
tance of the staff at the Manchester BSU. The Bioimaging Facility
microscopes used in this study were purchased with grants from
BBSRC, Wellcome, and the University of Manchester Strategic Fund.
Special thanks go to Robert Fernandez for help with the microscopy
and image processing.
REFERENCES
1. Muenzer, J.,Wraith, J. E., Clarke, L. A., and and the International Consen-
sus Panel on the Management and Treatment of Mucopolysaccharidosis,
I. (2009) Mucopolysaccharidosis I: Management and Treatment Guide-
lines. Pediatrics 123, 19–29
2. Wraith, J. E. (2005) The first 5 years of clinical experience with laronidase
enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin.
Pharmacother 6, 489–506
3. Wraith, J. E. (2006) Limitations of enzyme replacement therapy: current
and future. J. Inherit. Metab. Dis. 29, 442–447
4. Wilkinson, F. L., Sergijenko, A., Langford-Smith, K. J., Malinowska, M.,
Wynn, R. F., and Bigger, B. W. (2013) Busulfan conditioning enhances
engraftment of hematopoietic donor-derived cells in the brain compared
with irradiation.Molecular Therapy 21, 868–876
5. Boelens, J. J., Rocha, V., Aldenhoven, M., Wynn, R., O’Meara, A., Michel,
G., Ionescu, I., Parikh, S., Prasad, V. K., Szabolcs, P., Escolar, M., Gluck-
man, E., Cavazzana-Calvo,M., Kurtzberg, J., Eurocord, I. e.W. P. o. E., and
Duke, U. (2009) Risk factor analysis of outcomes after unrelated cord
blood transplantation in patients with hurler syndrome. Biol. Blood Mar-
row Transplant 15, 618–625
6. Boelens, J. J., Wynn, R. F., O’Meara, A., Veys, P., Bertrand, Y., Souillet, G.,
Wraith, J. E., Fischer, A., Cavazzana-Calvo,M., Sykora, K.W., Sedlacek, P.,
Rovelli, A., Uiterwaal, C. S., andWulffraat, N. (2007) Outcomes of hema-
topoietic stem cell transplantation for Hurler’s syndrome in Europe: a risk
factor analysis for graft failure. Bone Marrow Transplant 40, 225–233
FIGURE 7.Working model of HS mediated HSPC migration and engraft-
ment defect inMPSI. A, in normalWTmice CXCL12 is produced by the bone
marrow and presented in a haptotactic gradient by HS. An equilibrium exists
between HS bound and unbound CXCL12. HSPCs are mainly retained in the
bone marrow by the CXCL12 gradient and some HS is required for CXCL12
dimerization and binding to CXCR4 receptors on HSPCs. Migration to bone
marrow is reliant on increased CXLC12 production by bone marrow cells. B,
bonemarrow cells in Idua/mice contain an excess of intra- andparticularly
extracellular HS that is highly sulfated and also elevated in the peripheral
blood. Despite increased CXCL12 levels in the Idua/ bone marrow niche,
increasedbinding of CXCL12byHS and thus sequestration leads to increased
retention of HSPCs within the bone marrow and reduced migration after
myeloablation. Full intensity myeloablation may not increase cell numbers
migrating over reduced intensity conditioning, but further damages the
recipient niche giving donor cells a selective advantage within the niche
despite the poor migratory environment present in MPSI.
Accumulated HS Inhibits HSPC Engraftment inMPSI
DECEMBER 26, 2014•VOLUME 289•NUMBER 52 JOURNAL OF BIOLOGICAL CHEMISTRY 36201
7. Wynn, R. F.,Wraith, J. E., Mercer, J., O’Meara, A., Tylee, K., Thornley, M.,
Church, H. J., and Bigger, B. W. (2009) Improved metabolic correction in
patients with lysosomal storage disease treated with hematopoietic stem
cell transplant compared with enzyme replacement therapy. J. Pediatr.
154, 609–611
8. de Ru,M.H., van der Tol, L., vanVlies, N., Bigger, B.W., Hollak, C. E., Ijlst,
L., Kulik, W., van Lenthe, H., Saif, M. A., Wagemans, T., van der Wal,
W.M.,Wanders, R. J., andWijburg, F. A. (2013) Plasma and urinary levels
of dermatan sulfate and heparan sulfate derived disaccharides after long-
term enzyme replacement therapy (ERT) in MPS I: correlation with the
timing of ERT and with total urinary excretion of glycosaminoglycans.
J. Inherited Metabolic Disease 36, 247–255
9. Fuller, M., Meikle, P. J., and Hopwood, J. J. (2004) Glycosaminoglycan
degradation fragments in mucopolysaccharidosis I. Glycobiology 14,
443–450
10. Holley, R. J., Deligny, A., Wei, W., Watson, H. A., Niñonuevo, M. R.,
Dagälv, A., Leary, J. A., Bigger, B. W., Kjellén, L., and Merry, C. L. (2011)
Mucopolysaccharidosis type I, unique structure of accumulated heparan
sulfate and increased N-sulfotransferase activity in mice lacking -l-idu-
ronidase. J. Biol. Chem. 286, 37515–37524
11. Murphy, J. W., Cho, Y., Sachpatzidis, A., Fan, C., Hodsdon, M. E., and
Lolis, E. (2007) Structural and functional basis of CXCL12 (stromal cell-
derived factor-1) binding to heparin. J. Biol. Chem. 282, 10018–10027
12. Netelenbos, T., Zuijderduijn, S., Van Den Born, J., Kessler, F. L., Zweeg-
man, S., Huijgens, P. C., and Dräger, A. M. (2002) Proteoglycans guide
SDF-1-induced migration of hematopoietic progenitor cells. J. Leukocyte
Biol. 72, 353–362
13. Proudfoot, A. E., Handel, T. M., Johnson, Z., Lau, E. K., LiWang, P., Clark-
Lewis, I., Borlat, F., Wells, T. N., and Kosco-Vilbois, M. H. (2003) Gly-
cosaminoglycan binding and oligomerization are essential for the in
vivo activity of certain chemokines. Proc. Natl. Acad. Sci. U.S.A. 100,
1885–1890
14. Kuschert, G. S. V., Coulin, F., Power, C. A., Proudfoot, A. E. I., Hubbard,
R. E., Hoogewerf, A. J., and Wells, T. N. C. (1999) Glycosaminoglycans
Interact SelectivelywithChemokines andModulate Receptor Binding and
Cellular Responses. Biochemistry 38, 12959–12968
15. Merry, C. L., Lyon, M., Deakin, J. A., Hopwood, J. J., and Gallagher, J. T.
(1999) Highly sensitive sequencing of the sulfated domains of heparan
sulfate. J. Biol. Chem. 274, 18455–18462
16. Wright, D. E., Bowman, E. P.,Wagers, A. J., Butcher, E. C., andWeissman,
I. L. (2002) Hematopoietic stem cells are uniquely selective in their migra-
tory response to chemokines. J. Exp. Med. 195, 1145–1154
17. Ceradini, D. J., Kulkarni, A. R., Callaghan, M. J., Tepper, O. M., Bastidas,
N., Kleinman,M. E., Capla, J. M., Galiano, R. D., Levine, J. P., and Gurtner,
G. C. (2004) Progenitor cell trafficking is regulated by hypoxic gradients
through HIF-1 induction of SDF-1. Nat. Med. 10, 858–864
18. Ponomaryov, T., Peled, A., Petit, I., Taichman, R. S., Habler, L., Sandbank,
J., Arenzana-Seisdedos, F., Magerus, A., Caruz, A., Fujii, N., Nagler, A.,
Lahav,M., Szyper-Kravitz,M., Zipori, D., and Lapidot, T. (2000) Induction
of the chemokine stromal-derived factor-1 following DNA damage im-
proves human stem cell function. J. Clin. Invest. 106, 1331–1339
19. O’Boyle, G., Mellor, P., Kirby, J. A., and Ali, S. (2009) Anti-inflammatory
therapy by intravenous delivery of non-heparan sulfate-binding CXCL12.
FASEB J. 23, 3906–3916
20. Sadir, R., Baleux, F., Grosdidier, A., Imberty, A., and Lortat-Jacob, H.
(2001) Characterization of the stromal cell-derived factor-1-heparin
complex. J. Biol. Chem. 276, 8288–8296
21. Clarke, L. A., Russell, C. S., Pownall, S., Warrington, C. L., Borowski, A.,
Dimmick, J. E., Toone, J., and Jirik, F. R. (1997) Murine mucopolysaccha-
ridosis type I: targeted disruption of the murine -L-iduronidase gene.
Hum. Mol. Genet. 6, 503–511
22. Langford-Smith, A., Wilkinson, F. L., Langford-Smith, K. J., Holley, R. J.,
Sergijenko, A., Howe, S. J., Bennett, W. R., Jones, S. A., Wraith, J., Merry,
C. L., Wynn, R. F., and Bigger, B. W. (2012) Hematopoietic Stem Cell and
Gene Therapy Corrects Primary Neuropathology and Behavior in Muco-
polysaccharidosis IIIA Mice.Molecular Therapy 20, 1610–1621
23. Sergijenko, A., Langford-Smith, A., Liao, A. Y., Pickford, C. E., McDer-
mott, J., Nowinski, G., Langford-Smith, K. J., Merry, C. L., Jones, S. A.,
Wraith, J. E., Wynn, R. F., Wilkinson, F. L., and Bigger, B. W. (2013)
Myeloid/Microglial Driven Autologous Hematopoietic Stem Cell Gene
Therapy Corrects a Neuronopathic Lysosomal Disease. Molecular Ther-
apy 21, 1938–1949
24. Siapati, E. K., Bigger, B. W., Miskin, J., Chipchase, D., Parsley, K. L., Mi-
trophanous, K., Themis, M., Thrasher, A. J., and Bonnet, D. (2005) Com-
parison ofHIV- and EIAV-based vectors on their efficiency in transducing
murine and human hematopoietic repopulating cells.Molecular Therapy
12, 537–546
25. Russo, F. P., Alison, M. R., Bigger, B. W., Amofah, E., Florou, A., Amin, F.,
Bou-Gharios, G., Jeffery, R., Iredale, J. P., and Forbes, S. J. (2006) The bone
marrow functionally contributes to liver fibrosis. Gastroenterology 130,
1807–1821
26. Baldwin, R. J., ten Dam, G. B., van Kuppevelt, T. H., Lacaud, G., Gallagher,
J. T., Kouskoff, V., and Merry, C. L. (2008) A developmentally regulated
heparan sulfate epitope defines a subpopulation with increased blood po-
tential during mesodermal differentiation. Stem cells 26, 3108–3118
27. Johnson, C. E., Crawford, B. E., Stavridis, M., Ten Dam, G., Wat, A. L.,
Rushton, G., Ward, C. M., Wilson, V., van Kuppevelt, T. H., Esko, J. D.,
Smith, A., Gallagher, J. T., and Merry, C. L. (2007) Essential alterations of
heparan sulfate during the differentiation of embryonic stem cells to Sox1-
enhanced green fluorescent protein-expressing neural progenitor cells.
Stem Cells 25, 1913–1923
28. Wilkinson, F. L., Holley, R. J., Langford-Smith, K. J., Badrinath, S., Liao, A.,
Langford-Smith, A.W.W., Cooper, J. D., Jones, S. A.,Wraith, J. E., Wynn,
R. F., Merry, C. L. R., and Bigger, B. W. (2012) Neuropathology in Mouse
Models of Mucopolysaccharidosis Type I, IIIA and IIIB. PLoS One 7,
e35787
29. Baxter, M. A., Wynn, R. F., Schyma, L., Holmes, D. K., Wraith, J. E., Fair-
bairn, L. J., and Bellantuono, I. (2005) Marrow stromal cells from patients
affected by MPS I differentially support haematopoietic progenitor cell
development. J. Inherit. Metab. Dis. 28, 1045–1053
30. Albanese, P., Caruelle, D., Frescaline, G., Delbé, J., Petit-Cocault, L., Huet,
E., Charnaux, N., Uzan, G., Papy-Garcia, D., and Courty, J. (2009) Glyco-
saminoglycan mimetics-induced mobilization of hematopoietic progeni-
tors and stem cells into mouse peripheral blood: structure/function in-
sights. Exp. Hematol. 37, 1072–1083
31. Sweeney, E. A., and Papayannopoulou, T. (2001) Increase in circulating
SDF-1 after treatment with sulfated glycans. The role of SDF-1 in mobili-
zation. Ann. N.Y. Acad. Sci. 938, 48–52; discussion 52–43
32. Gupta, P. (2006) Impairment of the activity of glycosaminoglycan-binding
cytokines by functionally abnormal heparan sulfates: a novel mechanism
underlying disease pathophysiology. Scientific World Journal 6, 452–456
33. Khan, S. A., Nelson, M. S., Pan, C., Gaffney, P. M., and Gupta, P. (2008)
Endogenous Heparan Sulfate and Heparin Modulate Bone Morphoge-
netic Protein-4 (BMP-4) Signaling And Activity. Am. J. Physiol. Cell
Physiol. 294, 1387–1397
34. Pan, C., Nelson, M. S., Reyes, M., Koodie, L., Brazil, J. J., Stephenson, E. J.,
Zhao, R. C., Peters, C., Selleck, S. B., Stringer, S. E., and Gupta, P. (2005)
Functional abnormalities of heparan sulfate in mucopolysaccharidosis-I
are associated with defective biologic activity of FGF-2 on human multi-
potent progenitor cells. Blood 106, 1956–1964
35. Deakin, J. A., and Lyon, M. (2008) A simplified and sensitive fluorescent
method for disaccharide analysis of both heparan sulfate and chondroitin/
dermatan sulfates from biological samples. Glycobiology 18, 483–491
36. Lensen, J. F., Rops, A. L., Wijnhoven, T. J., Hafmans, T., Feitz, W. F.,
Oosterwijk, E., Banas, B., Bindels, R. J., van den Heuvel, L. P., van der Vlag,
J., Berden, J. H., and van Kuppevelt, T. H. (2005) Localization and func-
tional characterization of glycosaminoglycan domains in the normal hu-
man kidney as revealed by phage display-derived single chain antibodies.
J. Am. Soc. Nephrol. 16, 1279–1288
37. Ten Dam, G. B., Kurup, S., van de Westerlo, E. M., Versteeg, E. M., Lin-
dahl, U., Spillmann, D., and van Kuppevelt, T. H. (2006) 3-O-sulfated
oligosaccharide structures are recognized by anti-heparan sulfate anti-
body HS4C3. J. Biol. Chem. 281, 4654–4662
38. vanKuppevelt, T.H., Dennissen,M.A., vanVenrooij,W. J., Hoet, R.M.A.,
and Veerkamp, J. H. (1998) Generation and Application of Type-specific
Anti-Heparan Sulfate Antibodies Using Phage Display Technology. Fur-
Accumulated HS Inhibits HSPC Engraftment inMPSI
36202 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 52•DECEMBER 26, 2014
ther Evidence for Heparan Sulfate Heterogeneity in the Kidney. J. Biol.
Chem. 273, 12960–12966
39. Saif, M. A., Bigger, B. W., Brookes, K. E., Mercer, J., Tylee, K. L.,
Church, H. J., Bonney, D. K., Jones, S., Wraith, J. E., and Wynn, R. F.
(2012) Hematopoietic stem cell transplantation improves the high in-
cidence of neutralizing allo-antibodies observed in Hurler’s syndrome
after pharmacological enzyme replacement therapy. Haematologica
97, 1320–1328
40. David, G., Bai, X. M., Van der Schueren, B., Cassiman, J. J., and Van den
Berghe, H. (1992) Developmental changes in heparan sulfate expression:
in situ detection with mAbs. J. Cell Biol. 119, 961–975
41. Wilson, S., Hashamiyan, S., Clarke, L., Saftig, P.,Mort, J., Dejica, V.M., and
Brömme, D. (2009) Glycosaminoglycan-mediated loss of cathepsin K col-
lagenolytic activity in MPS I contributes to osteoclast and growth plate
abnormalities. Am. J. Pathol. 175, 2053–2062
42. Lawrence, R., Brown, J. R., Al-Mafraji, K., Lamanna, W. C., Beitel, J. R.,
Boons, G. J., Esko, J. D., and Crawford, B. E. (2012) Disease-specific non-
reducing end carbohydrate biomarkers for mucopolysaccharidoses. Nat.
Chem. Biol. 8, 197–204
43. Rueda, P., Richart, A., Récalde, A., Gasse, P., Vilar, J., Guérin, C., Lortat-
Jacob, H., Vieira, P., Baleux, F., Chretien, F., Arenzana-Seisdedos, F., and
Silvestre, J. S. (2012) Homeostatic and tissue reparation defaults in mice
carrying selective genetic invalidation of CXCL12/proteoglycan interac-
tions. Circulation 126, 1882–1895
44. Langford-Smith, K., Arasaradnam,M.,Wraith, J. E.,Wynn, R., and Bigger,
B. W. (2010) Evaluation of heparin cofactor II-thrombin complex as a
biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB
mice.Molecular Genetics Metabolism 99, 269–274
45. Langford-Smith, K. J.,Mercer, J., Petty, J., Tylee, K., Church,H., Roberts, J.,
Moss, G., Jones, S., Wynn, R., Wraith, J. E., and Bigger, B. W. (2011)
Heparin cofactor II-thrombin complex and dermatan sulphate:chondroi-
tin sulphate ratio are biomarkers of short- and long-term treatment effects
in mucopolysaccharide diseases. J. Inherited Metab. Dis. 34, 499–508
46. Langford-Smith, K. J., Sandiford, Z., Langford-Smith, A., Wilkinson, F. L.,
Jones, S. A.,Wraith, J. E.,Wynn, R. F., and Bigger, B.W. (2013) Signal One
and Two Blockade Are Both Critical for Non-Myeloablative Murine
HSCT across a Major Histocompatibility Complex Barrier. PloS one 8,
e77632
Accumulated HS Inhibits HSPC Engraftment inMPSI
DECEMBER 26, 2014•VOLUME 289•NUMBER 52 JOURNAL OF BIOLOGICAL CHEMISTRY 36203
